A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)
Latest Information Update: 02 Jul 2025
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Pagoda
- Sponsors Roche
Most Recent Events
- 07 Feb 2025 Planned number of patients changed from 545 to 634.
- 07 Feb 2025 Planned primary completion date changed from 16 Sep 2022 to 16 Nov 2026.
- 07 Feb 2025 Status changed from active, no longer recruiting to recruiting.